Communications
We characterized the W37V-catalyzed ligation of aryl
azide 1 in terms of kinetics and specificity. First, we repeated
the HPLC assay, with negative controls in which ATP was
omitted or W37V was replaced by wild-type LplA. As
expected, product was only observed in the presence of
ATP and the W37V mutant (Figure 2b). We collected the
HPLC-purified product and characterized it by mass spec-
trometry. Figure 4 in the Supporting Information shows that
the mass corresponds to the calculated mass for one molecule
of aryl azide 1 plus one LAP–HP1 protein, minus water. Next,
we measured the kinetics of ligation. Using HPLC as readout,
we determined a rate of catalysis kcat = (0.31 Æ 0.04) sÀ1, which
surprisingly is even faster than the natural ligation reaction
(lipoylation of E2p: kcat = 0.25 sÀ1 [23]
Figure 5 in the Support-
;
ing Information). Separate measurements showed that the
Michaelis constant Km was 80 mm or less (data not shown),
which is considerably greater than the Km value of wild-type
lipoic acid for LplA (1.7 mm[21] or 4.5 mm[24]).
We were concerned that remodeling of the LplA active
site might change the peptide specificity of the enzyme.
Therefore, we characterized the specificity of W37V-cata-
lyzed aryl azide ligation in three ways. First, we prepared a
total lysate from HEK cells expressing a LAP fusion with
cyan fluorescent protein (LAP–CFP[23]). We labeled the lysate
under forcing conditions with aryl azide, ATP, and W37V
LplA, and then we derivatized the aryl azide with phosphine–
Flag conjugate by using the Staudinger ligation.[26] Western
blotting with anti-Flag antibody showed that, even though the
LAP–CFP expression level is so low that it cannot be detected
above endogenous proteins in the Coomassie-stained gel,
only LAP–CFP receives the aryl azide, and the endogenous
proteins in the lysate are not modified by W37V LplA
(Figure 2c). Negative controls showed that labeling is specific
for LAP and dependent on the W37V mutation (Figure 2c).
For our second specificity test, we performed ligation with
aryl azide 1 on three non-LAP proteins: FRB-AP, FKBP-
AP,[27] and BCCP-87.[28] We characterized the products by
mass spectrometry (data not shown). None were found to be
modified with aryl azide, despite exposure to reaction
conditions that gave complete conversion of LAP–HP1 into
the aryl azide conjugate.
Third, we tested peptide specificity by using a live cell
imaging assay. A useful feature of the aryl azide probe is that
it not only mediates photo-cross-linking but can also serve as
a functional-group handle for the introduction of fluorescent
probes. Although it is more common to derivatize alkyl azides
with alkynes through [3+2] cycloaddition[23,29] or with phos-
phines through the Staudinger ligation,[30–32] we and other
groups have observed facile reactions of aryl azides with both
cyclooctynes[33] and phosphines.[30–32] To make use of this
reactivity, we expressed a LAP–CFP–TM (transmembrane)
cell-surface construct[23] in HeLa cells and performed extrac-
ellular labeling with W37V LplA, aryl azide, and ATP. After
washing away excess aryl azide, we derivatized the LAP-
ligated azide with cyclooctyne–cyanine 3 (Cy3) conjugate.[23]
Imaging showed that only transfected (CFP-positive) cells
became labeled with Cy3, while neighboring untransfected
cells did not receive Cy3 (Figure 3). Negative controls with
aryl azide omitted from the labeling reaction or with LAP–
Figure 3. Specific fluorophore labeling on living cells through aryl
azide 1 ligation. HeLa cells expressing LAP–CFP–TM were labeled with
W37V LplA and aryl azide 1 for 40 min and, subsequently, with
cyclooctyne–Cy3 conjugate[22] for 20 min, to selectively derivatize the
aryl azide. Imaging shows pink Cy3 staining on the membranes of
transfected CFP-positive cells. Negative controls are shown with
omission of aryl azide (middle row)or with LAP–CFP–TM replaced by
an alanine mutant (bottom row). The CFP and Cy3 images are
merged. DIC: differential interference contrast.
CFP–TM replaced by an alanine point mutant in the LAP
sequence gave no fluorophore labeling (Figure 3). Thus, our
three assays collectively demonstrate that aryl azide ligation
has the same high sequence specificity as lipoylation catalyzed
by wild-type LplA.
To demonstrate the utility of the new aryl azide ligase, we
attempted to detect a known PPI within a complex mixture.
FKBP is known to interact with FRB in the presence but not
absence of the small molecule rapamycin.[34] We prepared an
FKBP–LAP construct and expressed it in HEK cells. In
separate HEK cells, we expressed a CFP–FRB fusion. Total
lysates were prepared from both samples, and they were
mixed. We labeled the combined lysates with aryl azide 1,
ATP, and W37V LplA, before photo-cross-linking with 300–
360 nm light in the presence or absence of rapamycin. We
analyzed the samples by sodium dodecylsulfate polyacryl-
amide gel electrophoresis (SDS PAGE) and detected CFP–
FRB by in-gel CFP fluorescence (Figure 4). Only imaging in
the presence of rapamycin with UV light applied and the LAP
tag intact did we observe a higher-molecular-weight band
corresponding to the covalent FKBP–FRB heterodimer.
Negative controls with either construct omitted gave no
heterodimer band.
In summary, we have engineered an aryl azide ligase that
brings us closer to the dream of routine PPI detection inside
living cells by photo-cross-linking. Our ligase, generated by
active-site engineering of E. coli LplA, catalyzes the
extremely sequence-specific covalent ligation of a fluorinated
aryl azide probe onto LAP fusion proteins, expressed on
ꢀ 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Angew. Chem. Int. Ed. 2008, 47, 7018 –7021